The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients

Clinical and Experimental Hypertension

Volumn 35, Issue 6, 2013, Pages 418-423

  Unlu, Murat ^a   Karaman, Murat ^b   Ay, Seyit Ahmet ^b   Balta, Sevket ^b   Cakar, Mustafa ^b   Demirkol, Sait ^b   Celik, Turgay ^b   Arslan, Erol ^b   Demirbas, Seref ^b   Turker, Turker ^b   Yaman, Halil ^b   Bulucu, Fatih ^b   Saǧlam, Kenan ^b  

^a Beytepe Hospital   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amlodipine; C reactive protein; Hypertension; Inflammation; Pentraxin; Valsartan

Indexed keywords

AMLODIPINE; C REACTIVE PROTEIN; PENTRAXIN 3; VALSARTAN;

ADULT; ARTICLE; CARDIOVASCULAR INFLAMMATION; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PROGNOSIS; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADULT; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SERUM AMYLOID P-COMPONENT; TETRAZOLES; VALINE; VASCULITIS;

EID: 84884546731     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.739237     Document Type: Article

References (31)

1. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17(4):223-230.
2. Davey Smith G, Lawlor DA, Harbord R, et al. Association of Creactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25(5):1051-1056.
3. Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53(1):95-102.
4. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. J Assoc Physicians 2003; 96(11):793-807.
5. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272 (52):32817-32823.
6. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204(4):793-804.
7. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension 2011; 57(2):132-140.
8. ManciaG,De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Euro Heart J 2007; 28(12):1462-1536.
9. Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens 2007; 9(2):103-112.
10. Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Human Hypertens 1991; 5(Suppl 1):61-66.
11. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc 2003; 289(19):2560-2572.
12. Morillas P, de Andrade H, Castillo J, et al. Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Rev Esp Cardiol 2012; 65(9):819-825.
13. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44(12):2841-2850.
14. Yano Y, Hatakeyama K. Inflammation and hypertension: new clinical information on pentraxin-3. Anadolu Kardiyol Derg 2012; 12(4):305-306.
15. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vasc Pharmacol 2006; 45(5):326-330.
16. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2(5):889-897.
17. Parlak A, Aydo?an U, Iyisoy A, et al. Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg 2012; 12(4):298-304.
18. Parlak A, Iyisoy A, Aydogan U, Cakir E, Saglam K. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients. Med Hypotheses 2012; 79(3):294-298.
19. Yilmaz MI, Carrero JJ, Martín-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5(7):1174-1181.
20. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3):646-661.
21. Marfella R, Siniscalchi M, Nappo F, et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18(3):308-318.
22. Moubarak M, Jabbour H, Smayra V, et al. Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol Res 2012; 61(1):13-24.
23. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am College Cardiol 2001; 37(2):440-444.
24. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on proinflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46(6):735-739.
25. Suleyman H, Halici Z, Hacimuftuoglu A, Gocer F. Role of adrenal gland hormones in antiinflammatory effect of calcium channel blockers. Pharmacol Rep 2006; 58(5):692-699.
26. Kataoka C, Egashira K, Ishibashi M, et al. Novel antiinflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 2004; 286(2):H768-H774.
27. Shishido T, Konta T, Nishiyama S, et al. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin Exp Hypertens 2011; 33(2):117-123.
28. Yilmaz R, Altun B, Kahraman S, Ozer N, Akinci D, Turgan C. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Renal Fail 2010; 32(8):903-912.
29. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008; 30(3):267-276.
30. Yoshii T, Iwai M, Li Z, et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29(6):457-466.
31. Martín-Ventura JL, Muñoz-Garcia B, Blanco-Colio LM, et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl 2008; 111:S71-S74